文献速递多重用药老年慢病共病管理

多病共存老年患者药物不良反应的检测与预防

Detection and prevention of adverse drug reactions in multi-morbid older patients.
PubMed 文献 · Age Ageing · 2019-01-01

本文综述多病共存老年患者药物不良反应(ADR)的检测、预测与预防研究。住院多病共存老年人ADR发生率可高达39%,其中多达三分之二可预防;当前最大障碍是人群与研究方法异质性大,缺乏标准化ADR预测、检测、因果评估与预防方法。

要点

  • 住院多病共存老年患者ADR发生率可高达39%,多达三分之二可预防。
  • 现有ADR预测方法用于异质性多病共存人群普遍不令人满意。
  • 缺乏标准化ADR预测、检测、因果评估与预防方法。

核心结论

  • 多病共存老年患者ADR常见且部分可预防,但缺乏标准化方法使预防困难。
  • 针对特定药物类别的风险可能比仅用患者特征更好地预测ADR发生。

研究设计与样本

  • 本文为评论性文章,总结当前多病共存老年患者ADR检测、预测与预防的主流研究。

主要发现

  • 既往研究估计至少十分之一住院老年患者会发生ADR。
  • 近期研究显示住院多病共存老年人ADR发生率可高达39%。
  • 这些ADR中多达三分之二可被认为可预防。
  • 文献中最大障碍是人群与研究方法存在 large heterogeneity。
  • 标准可用ADR预测方法用于异质性多病共存人群一般不满意。

临床怎么用

  • 临床应关注常导致多病共存住院老年患者重大ADR的 culprit 药物类别。
  • 在缺乏可靠ADR风险预测工具时,多病共存老年患者ADR预防具有挑战性。

局限性

  • 文献中人群与研究方法异质性大,难以理解和比较ADR研究。
  • 缺乏普遍接受的标准化ADR预测、检测、因果评估与预防方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adverse drug reactions (ADRs) are a recognised unintentional form of iatrogenic harm, which commonly occur in older adults who have high levels of multi-morbidity and associated polypharmacy. Previous studies estimate that at least one in 10 hospitalised older patients will experience an ADR. While recent research indicates that this could be as high as 39% in hospitalised multi-morbid, older adults, up to two-thirds of these ADRs can be considered preventable and therefore potentially avoidable. In addition to increasing patient morbidity and contributing to avoidable mortality, there is an associated cost implication with ADR occurrence. This commentary summarises current mainstream research in terms of ADR detection, prediction and prevention in multi-morbid older patients. At present, the biggest barrier to understanding and comparing ADRs in the literature is the large heterogeneity that exists in the population and study methods. Furthermore, there is the lack of standardised universally accepted methodology for ADR prediction, detection, causality assessment and subsequent prevention in older people. Standard available methods of ADR prediction applied to a heterogeneous multi-morbid population are generally unsatisfactory. Without an instrument that consistently and reliably predicts ADR risk in a reproducible manner, ADR prevention in multi-morbid older patients is challenging. Further attention should be focused on the culprit drugs that commonly lead to major ADRs in older multi-morbid hospitalised patients with polypharmacy. Risk associated with particular drug classes may possibly predict ADR occurrence better than patient characteristics alone. Current research is examining this drug class focus for ADR prevention in multi-morbid older people.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Jennings E, Gallagher P, O'Mahony D, et al. Detection and prevention of adverse drug reactions in multi-morbid older patients. Age Ageing. 2019. PMID: 30299453. doi:10.1093/ageing/afy157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。